Klaria signs agreement for EU grant worth ca. 21 MSEK to take migraine product to market
Klaria Pharma Holding AB (publ) announces that the company has finalized and signed the agreement for the grant of 21 MSEK in total from the EU Horizon 2020 program. The grant will, as announced earlier, be used to finalize the development and commerzialisation of KL-00119, the company’s leading candidate for treatment of acute migraine-related pain.The EU grant, with agreement number 829615, is expected to cover the costs for all of the remaining activities in the KL-00119 project up to and including a potential market registration in Europe, the United States and Canada. The remaining